Fig. 1From: Safety and efficacy of mTOR inhibitor treatment in patients with tuberous sclerosis complex under 2 years of age – a multicenter retrospective studyReasons for initiation of mTOR inhibitor treatment. CR cardiac rhabdomyoma. SEGA subependymal giant cell astrocytoma.Back to article page